L. Becker Hewes - 01 Mar 2025 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: BPMC
Reported as of: 01 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2025, 17:21:45 UTC
Prior SEC filing: 06 Jun 2024
Next SEC filing: 07 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Melissa Masse, Attorney-in-Fact

Key filing fact

L. Becker Hewes filed Form 4 for Blueprint Medicines Corp (BPMC) on 04 Mar 2025.

Key facts

This page summarizes L. Becker Hewes's Form 4 filing for Blueprint Medicines Corp (BPMC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2025, 17:21.

Change

Previous filing in this sequence was filed on 06 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BPMC transaction

Common Stock

Award

Transaction value: $0
Shares: +11,000
Change %: +37%
Price: $0.000000
Shares after: 40,514
Date: 01 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BPMC transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +22,000
Change %
Price: $0.000000
Shares after: 22,000
Date: 01 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $96.57
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported transaction involved the Reporting Person's receipt of a grant of 11,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan.

Footnote F2

This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter.